Literature DB >> 29955870

Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?

Eudocia Quant Lee1, J Ricardo McFaline-Figueroa1, Timothy F Cloughesy2, Patrick Y Wen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29955870      PMCID： PMC6280142          DOI： 10.1093/neuonc/noy092

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

1.  Irinotecan therapy in adults with recurrent or progressive malignant glioma.

Authors:  H S Friedman; W P Petros; A H Friedman; L J Schaaf; T Kerby; J Lawyer; M Parry; P J Houghton; S Lovell; K Rasheed; T Cloughsey; E S Stewart; O M Colvin; J M Provenzale; R E McLendon; D D Bigner; I Cokgor; M Haglund; J Rich; D Ashley; J Malczyn; G L Elfring; L L Miller
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

2.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

Authors:  Michael D Prados; Kathleen Lamborn; W K A Yung; Kurt Jaeckle; H Ian Robins; Minesh Mehta; Howard A Fine; Patrick Y Wen; Timothy Cloughesy; Susan Chang; M Kelly Nicholas; David Schiff; Harry Greenberg; Larry Junck; Karen Fink; Ken Hess; John Kuhn
Journal:  Neuro Oncol       Date:  2006-03-13       Impact factor: 12.300

Review 3.  Experience with irinotecan for the treatment of malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; David A Reardon; Henry S Friedman
Journal:  Neuro Oncol       Date:  2008-09-10       Impact factor: 12.300

4.  Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Authors:  Tracy T Batchelor; Mark R Gilbert; Jeffrey G Supko; Kathryn A Carson; Louis B Nabors; Stuart A Grossman; Glenn J Lesser; Tom Mikkelsen; Surasak Phuphanich
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

5.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

6.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  6 in total
  1 in total

1.  Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents.

Authors:  Wenjie Wang; Monica Rodriguez-Silva; Arlet M Acanda de la Rocha; Aizik L Wolf; Yanhao Lai; Yuan Liu; William C Reinhold; Yves Pommier; Jeremy W Chambers; Yuk-Ching Tse-Dinh
Journal:  Cancers (Basel)       Date:  2019-09-23       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.